Zobrazeno 1 - 10
of 327
pro vyhledávání: ''
Autor:
Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
Publikováno v:
Lung Cancer. 174:91-96
The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity
Autor:
Alexis B. Cortot, Didier Debieuvre, L. Moreau, Radj Gervais, Jacques Margery, Julien Mazieres, Olivier Molinier, Michel Poudenx, Alexandra Langlais, Nicolas Girard, Patrick Dumont, Gérard Zalcman, Franck Morin, Virginie Westeel, Pierre-Jean Souquet, Eric Pichon, Fabrice Barlesi, Maurice Pérol, Jérôme Dauba, Jacques Cadranel, Clarisse Audigier-Valette, Denis Moro-Sibilot
Publikováno v:
Lung Cancer. 164:84-90
Benefit from maintenance in advanced non-squamous non-small cell lung cancer (NS-NSCLC) might favor switch maintenance after disease stabilization (SD) and continuation after objective response (OR). This trial assessed a maintenance strategy conditi
Autor:
Didier, Debieuvre, Charles, Dayen, Adrien, Dixmier, David, Pau, Anna, Sibley-Revelat, William, Greenwood, Samuel, Gally, Lionel, Falchero
Publikováno v:
Lung Cancer. 164:1-7
FRESC reanalyzed extensive-stage small-cell lung cancer (ES-SCLC) patient data from the French KBP-2010 cohort to describe the characteristics and therapeutic management of ES-SCLC and provide real-world estimates of survival.A target population of f
Autor:
Nicolas Girard, Gaëtane Simon, Maurice Pérol, Thomas Filleron, Christos Chouaid, Roland Schott, Matthieu Carton, Clarisse Audigier Valette, Mathieu Robain, Xavier Quantin, Didier Debieuvre, Radj Gervais, Hervé Lena, Bruno Coudert
Publikováno v:
Lung Cancer. 162:119-127
Background Cisplatin-based chemotherapy administered concurrently to thoracic radiation therapy is the recommended treatment for fit patients with unresectable stage III NSCLC. The aim of this study was to describe patient profiles and clinical outco
Publikováno v:
Lung Cancer
Objectives Second-line immune checkpoint inhibition (ICI) was recently shown to have a survival advantage over placebo in malignant pleural mesothelioma (MPM), but the survival comparison to chemotherapy in patients with MPM receiving routine clinica
Autor:
Isamu Okamoto, Yuichi Takiguchi, Nobuyuki Yamamoto, Ichiro Yoshino, Takehito Shukuya, Etsuo Miyaoka, Koichi Takayama, Kazuhisa Takahashi, Yasushi Shintani, Meinoshin Okumura, Katsuhiko Naoki, Satoshi Igawa, Ikuo Sekine, Katsuyuki Kiura, Akira Inoue
Publikováno v:
Lung Cancer. 146:160-164
Objectives Most patients with small-cell lung cancer (SCLC) experience relapse because of the emergence of drug-resistant tumor cells. Therefore, second-line therapy is subsequently required to prolong their survival. However, it is unclear whether s
Autor:
Anas Gazzah, Pilar Garrido, Alexis B. Cortot, Jaafar Bennouna, Melissa Lynne Johnson, Maciej Gil, Haruyasu Murakami, Benjamin Besse
Publikováno v:
Lung Cancer. 142:63-69
Objectives Efficacy and safety of necitumumab when combined with pembrolizumab was assessed in patients with Stage IV non-small cell lung cancer (NSCLC) of squamous and nonsquamous histology, who had progressed after treatment with a platinum-based d
Autor:
Takashi Seto, Noboru Yamamoto, Takeharu Yamanaka, Yuichiro Ohe, Makoto Nishio, Tatsuya Yoshida, Toyoaki Hida, Akira Ono, Takayasu Kurata, Kentaro Sakamaki, Hiroaki Okamoto, Miyako Satouchi, Seiji Niho, Koichi Goto, Tetsuo Akimoto
Publikováno v:
Lung Cancer. 141:64-71
Objectives SPECTRA is a multicenter, randomized phase II study of chemotherapy with cisplatin (CDDP) plus S-1 versus CDDP plus pemetrexed (PEM) in combination with thoracic radiotherapy (TRT) for locally advanced non-squamous non-small cell lung canc
Autor:
Alvin Soon Tiong Lim, Quan Sing Ng, Anantham Devanand, Daniel S.W. Tan, T. Rajasekaran, Eng Huat Tan, Zaw Win Aung, Chee Keong Toh, G. Lai, Chow Wei Too, Tony Kiat-Hon Lim, Aaron C. Tan, Bien Soo Tan, Tina P.T. Koh, Tse Hui Lim, Mei-Kim Ang, Angela Takano, Wan Ling Tan, Shou Yu Poon, Brett Doble, Apoorva Gogna, Amit Jain, Boon-Hean Ong, Ravindran Kanesvaran, Wan-Teck Lim, Gek San Tan
Publikováno v:
Lung Cancer. 139:207-215
Objectives There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsie
Publikováno v:
Lung Cancer. 138:52-57
Brain metastasis (BM) is common in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer. However, the brain surveillance strategy during treatment in advanced lung cancer patients varies, and the impact on clinical outcome is uncl